527 related articles for article (PubMed ID: 10454950)
21. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL; Figgitt DP
Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
[TBL] [Abstract][Full Text] [Related]
22. International Diabetes Federation meeting, 1997. Issues in the treatment of type 2 diabetes; sulfonylureas, metformin, and troglitazone.
Bloomgarden ZT
Diabetes Care; 1998 Jun; 21(6):1024-6. PubMed ID: 9614626
[No Abstract] [Full Text] [Related]
23. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus.
Inzucchi SE; Maggs DG; Spollett GR; Page SL; Rife FS; Walton V; Shulman GI
N Engl J Med; 1998 Mar; 338(13):867-72. PubMed ID: 9516221
[TBL] [Abstract][Full Text] [Related]
24. Troglitazone in type II diabetes mellitus.
Sparano N; Seaton TL
Pharmacotherapy; 1998; 18(3):539-48. PubMed ID: 9620105
[TBL] [Abstract][Full Text] [Related]
25. [Drug therapy in subjects with impaired glucose tolerance].
Kawamori R; Yoshii H
Nihon Rinsho; 1996 Oct; 54(10):2750-3. PubMed ID: 8914439
[TBL] [Abstract][Full Text] [Related]
26. Drug administration in patients with diabetes mellitus. Safety considerations.
Gilbert RE; Cooper ME; Krum H
Drug Saf; 1998 Jun; 18(6):441-55. PubMed ID: 9638389
[TBL] [Abstract][Full Text] [Related]
27. Combination oral agent and insulin therapy for type 2 diabetes mellitus.
Passaro MD; Ratner RE
Curr Diab Rep; 2001 Oct; 1(2):106-11. PubMed ID: 12643105
[TBL] [Abstract][Full Text] [Related]
28. Troglitazone: a review of its use in the management of type 2 diabetes mellitus.
Plosker GL; Faulds D
Drugs; 1999 Mar; 57(3):409-38. PubMed ID: 10193691
[TBL] [Abstract][Full Text] [Related]
29. [Troglitazone].
Yamanouchi T
Nihon Rinsho; 2000 Feb; 58(2):389-94. PubMed ID: 10707563
[TBL] [Abstract][Full Text] [Related]
30. Economic assessment of troglitazone as an adjunct to sulfonylurea therapy in the treatment of type 2 diabetes.
Caro JJ; Klittich WS; Raggio G; Kavanagh PL; O'Brien JA; Shomphe LA; Flegel KM; Copley-Merriman C; Sigler C
Clin Ther; 2000 Jan; 22(1):116-27. PubMed ID: 10688395
[TBL] [Abstract][Full Text] [Related]
31. Type II diabetes mellitus.
Edelman SV
Adv Intern Med; 1998; 43():449-500. PubMed ID: 9506190
[TBL] [Abstract][Full Text] [Related]
32. Where thiazolidinediones will fit.
Reasner CA
Diabetes Metab Res Rev; 2002; 18 Suppl 2():S30-5. PubMed ID: 11921436
[TBL] [Abstract][Full Text] [Related]
33. Treatment of type 2 diabetes mellitus.
Feinglos MN; Bethel MA
Med Clin North Am; 1998 Jul; 82(4):757-90. PubMed ID: 9706120
[TBL] [Abstract][Full Text] [Related]
34. Targeted glycemic control in type 2 diabetes.
Skyler JS
J Fla Med Assoc; 1998 Aug; 85(2):7-15. PubMed ID: 9782713
[No Abstract] [Full Text] [Related]
35. Oral pharmacologic management of type 2 diabetes.
Riddle MC
Am Fam Physician; 1999 Dec; 60(9):2613-20. PubMed ID: 10605995
[TBL] [Abstract][Full Text] [Related]
36. Pharmacologic treatment options for non-insulin-dependent diabetes mellitus.
Tan GH; Nelson RL
Mayo Clin Proc; 1996 Aug; 71(8):763-8. PubMed ID: 8691897
[TBL] [Abstract][Full Text] [Related]
37. Recent advances in the treatment of type II diabetes mellitus.
Baliga BS; Fonseca VA
Am Fam Physician; 1997 Feb; 55(3):817-24. PubMed ID: 9048504
[TBL] [Abstract][Full Text] [Related]
38. New agents for Type 2 diabetes.
Nattrass M; Bailey CJ
Baillieres Best Pract Res Clin Endocrinol Metab; 1999 Jul; 13(2):309-29. PubMed ID: 10761869
[TBL] [Abstract][Full Text] [Related]
39. Managing type 2 diabetes. A look at the newer agents.
Larmore SS
JAAPA; 1999 Jun; 12(6):47-8, 51-4, 57. PubMed ID: 10728087
[No Abstract] [Full Text] [Related]
40. Troglitazone but not metformin restores insulin-stimulated phosphoinositide 3-kinase activity and increases p110beta protein levels in skeletal muscle of type 2 diabetic subjects.
Kim YB; Ciaraldi TP; Kong A; Kim D; Chu N; Mohideen P; Mudaliar S; Henry RR; Kahn BB
Diabetes; 2002 Feb; 51(2):443-8. PubMed ID: 11812753
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
